Evaluation of kudesan efficacy in hypertensive patients with diabetes mellitus type 2

The purpose of the study was to evaluate the efficacy of therapy with Kudesan (coenzyme Q10) in patients with arterial hypertension and diabetes mellitus type 2. Patients who received coenzyme Q10 additionally to baseline therapy experienced a significant reduction in systolic and diastolic blood pressure by 6.1±5.3 mm Hg (p=0.02) and by 2.9±1.4 (p=0.048), respectively; decrease in blood glucose level by 1.26±1.12; р=0.01); and reduction of glycosylated hemoglobin by 0.37±0.17% (p=0.034) in comparison with baseline data. Data provided evidence that administration of coenzyme Q10 in patients with diabetes mellitus type 2 contributed to control of arterial blood pressure and glycemia level. A decrease in a dose or even a discontinuation of one of the antihypertensive drugs was achieved in 73% of patients who received additional coenzyme Q10 therapy. Kudesan therapy was safe in regard to all biomedical characteristics studied and led to significant decrease in total blood cholesterol, triglyceride, and low density lipoprotein levels and increase in high density lipoprotein level. Patients reported about good overall health. According to data obtained with the Quality of Life questionnaire, MOS SF36 (MOS 36item shortform health survey), indicators of psychological and physical health significantly improved. Improved control of arterial blood pressure may contribute to increase of patients life expectancy due to decreased risk of cardiovascular complications.